Robert G Wilcox
Overview
Explore the profile of Robert G Wilcox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baker J, Wilcox R
Thorax
. 2016 Dec;
72(3):271-276.
PMID: 27927840
Treating people with cardiovascular disease and COPD causes significant clinician anxiety. β-Blockers save lives in people with heart disease, specifically postinfarction and heart failure. COPD and heart disease frequently coexist...
2.
Gershlick A, Westerhout C, Armstrong P, Huber K, Halvorsen S, Steg P, et al.
Heart
. 2015 Feb;
101(9):692-8.
PMID: 25691510
Objectives: Primary percutaneous coronary intervention (P-PCI) is the preferred reperfusion option in ST-elevation myocardial infarction, but its benefits become attenuated as time to its potential delivery becomes prolonged. Based on...
3.
Welsh R, Van de Werf F, Westerhout C, Goldstein P, Gershlick A, Wilcox R, et al.
Am J Cardiol
. 2014 Aug;
114(6):811-9.
PMID: 25108302
Although a fibrinolytic pharmacoinvasive strategy is recommended for patients with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (PCI), there are limited data addressing outcomes...
4.
Armstrong P, Westerhout C, Van de Werf F, Califf R, Welsh R, Wilcox R, et al.
Am Heart J
. 2011 May;
161(5):848-54.
PMID: 21570513
Background: Traditional time-to-event analysis assigns equal weight to the first event in the composite end point. This is counterintuitive to many stakeholders. Methods: We constructed weights for components of a...
5.
Simes R, OConnell R, Aylward P, Varshavsky S, Diaz R, Wilcox R, et al.
Am Heart J
. 2010 Jun;
159(6):988-97.
PMID: 20569711
Background: Despite advances in therapy, global mortality due to acute myocardial infarction remains high. The international Hirulog and Early Reperfusion or Occlusion (HERO-2) trial of 17,073 patients with ST-segment elevation...
6.
Fazal I, AlFakih K, Wilcox R, Walsh J
Int J Cardiol
. 2008 Mar;
134(1):138-9.
PMID: 18372062
Unlabelled: Aortic stenosis (AS) is the most common indication for valve surgery. Recent data suggested an increased risk of cerebral emboli when the aortic valve is crossed to obtain 'pull-back'...
7.
Erdmann E, Wilcox R
Eur Heart J
. 2008 Jan;
29(1):12-20.
PMID: 18167366
Type 2 diabetes and heart failure commonly occur together and this combination is associated with poor outcomes. The relationship is likely to be multifactorial and also may involve a specific,...
8.
Xavier R, White A, Fox S, Wilcox R, Heptinstall S
Thromb Haemost
. 2007 Dec;
98(6):1266-75.
PMID: 18064324
The effects on platelet function of temperatures attained during hypothermia used in cardiac surgery are controversial. Here we have performed studies on platelet aggregation in whole blood and platelet-rich plasma...
9.
Storey R, Husted S, Harrington R, Heptinstall S, Wilcox R, Peters G, et al.
J Am Coll Cardiol
. 2007 Nov;
50(19):1852-6.
PMID: 17980251
Objectives: In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel...
10.
Erdmann E, Charbonnel B, Wilcox R, Skene A, Massi-Benedetti M, Yates J, et al.
Diabetes Care
. 2007 Aug;
30(11):2773-8.
PMID: 17666462
Objective: PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any...